Literature DB >> 16985864

Duloxetine: a new pharmacologic therapy for stress urinary incontinence.

Victor W Nitti.   

Abstract

The dual serotonin (5-HT)/norepinephrine (NE) reuptake inhibitor duloxetine shows promise as a pharmacologic therapy for stress urinary incontinence. This agent modulates lower urinary tract function through selective inhibition of 5-HT and NE receptor sites. It works centrally at Onuf's nucleus to increase activity of the pudendal nerve. Duloxetine facilitates sphincter activity during urine storage but not during voiding, maintaining the bladder-sphincter synergy. Because it inhibits both 5-HT and NE reuptake, duloxetine appears to offer an advantage over agents that inhibit reuptake of a single neurotransmitter.

Entities:  

Year:  2004        PMID： 16985864      PMCID： PMC1472858     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


  25 in total

Review 1.  Pharmacology of the lower urinary tract.

Authors:  W C de Groat; N Yoshimura
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

2.  Phenylpropanolamine and other OTC alpha-adrenergic agonists.

Authors: 
Journal:  Med Lett Drugs Ther       Date:  2000-12-11       Impact factor: 1.909

3.  Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors.

Authors:  F P Bymaster; L J Dreshfield-Ahmad; P G Threlkeld; J L Shaw; L Thompson; D L Nelson; S K Hemrick-Luecke; D T Wong
Journal:  Neuropsychopharmacology       Date:  2001-12       Impact factor: 7.853

4.  Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.

Authors:  Michael H Skinner; Han-Yi Kuan; Alan Pan; Korbtham Sathirakul; Mary Pat Knadler; Celedon R Gonzales; Kwee Poo Yeo; Shobha Reddy; Maggie Lim; Mosun Ayan-Oshodi; Stephen D Wise
Journal:  Clin Pharmacol Ther       Date:  2003-03       Impact factor: 6.875

5.  Comparison of treatment outcomes for imipramine for female genuine stress incontinence.

Authors:  H H Lin; B C Sheu; M C Lo; S C Huang
Journal:  Br J Obstet Gynaecol       Date:  1999-10

Review 6.  Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: implications for treating stress urinary incontinence.

Authors:  Karl B Thor
Journal:  Urology       Date:  2003-10       Impact factor: 2.649

7.  Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats.

Authors:  Mary A Katofiasc; Jeffrey Nissen; James E Audia; Karl B Thor
Journal:  Life Sci       Date:  2002-08-02       Impact factor: 5.037

Review 8.  Estrogen and urinary incontinence in women.

Authors:  C J Sultana; M D Walters
Journal:  Maturitas       Date:  1994-12       Impact factor: 4.342

9.  Effect of long-term administration of duloxetine on the function of serotonin and noradrenaline terminals in the rat brain.

Authors:  L E Rueter; K Kasamo; C de Montigny; P Blier
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1998-06       Impact factor: 3.000

10.  Serotoninergic, noradrenergic, and peptidergic innervation of Onuf's nucleus of normal and transected spinal cords of baboons (Papio papio).

Authors:  N Rajaofetra; J G Passagia; L Marlier; P Poulat; F Pellas; F Sandillon; B Verschuere; D Gouy; M Geffard; A Privat
Journal:  J Comp Neurol       Date:  1992-04-01       Impact factor: 3.215
View more
  1 in total

1.  Duloxetine for the treatment of post-prostatectomy stress urinary incontinence.

Authors:  Donald Neff; Amy Guise; Michael L Guralnick; Peter Langenstroer; William A See; Kenneth M Jacobsohn; R Corey O'Connor
Journal:  Can Urol Assoc J       Date:  2013 May-Jun       Impact factor: 1.862
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.